COVID-19 Immunization Guide For B.C. Pharmacies: Pfizer

Pfizer Vaccine in Pharmacies

Updated: Sept. 16, 2021 at 12:10 p.m. PDT

This guidance is developed with the British Columbia Ministry of Health

August 12, 2021

Vaccine: COVID-19 mRNA Vaccine – Pfizer-BioNTech

Priority group: Pfizer is indicated in individuals 12 years of age and older. Pharmacies can provide a complete series of the vaccine (dose 1 and/or dose 2).

Age is based on year of birth (i.e., the vaccine may be offered to individuals who will be turning 12 years of age within the current calendar year), per Provincial Health Officer recommendations.

ImmsBC System

ImmsBC is the provincial central booking and inventory system for COVID-19 vaccines. Pharmacies involved in the Pfizer pilot program must be registered with the ImmsBC system. This program evaluates the potential expanded use of ImmsBC system in pharmacies to support the provincial Dose 3 program. Click here to access the instructions and training content for the ImmsBC system.

Training and Education

*Check ImmsBC and CareConnect for complete patient history of immunizations.

Community Pharmacy Standards of Practice

  • Pharmacists providing immunizations must follow the College’s Standards, Limits and Condition for Drug Administration by Injection and Intranasal Route.
  • Pharmacists must follow the Community Pharmacy Standards of Practice.
    • Patient counselling
      • If a drug-related problem is identified during pharmacist/patient consultation, the pharmacist must take appropriate action to resolve the problem.
      • At a minimum, the pharmacist must confirm that the right patient is getting the right drug /strength and must also provide a direct opportunity for the patient to ask questions.
    • Reviewing PharmaNet*
      • A pharmacist must review the patient’s personal health information stored on the PharmaNet database before dispensing a drug and take appropriate action if necessary with respect to, but not limited to, appropriateness of drug therapy, drug interactions, allergies, adverse drug reactions, and therapeutic duplication.
    • Performing a final check
      • A pharmacist must review the prescription label to ensure it is consistent with the prescription and/or hardcopy.
      • Always check the expiry date of the product before providing the vaccine. Rotate vaccines according to expiry date (place those with the longest expiry date at the back)
  • For cold chain management, pharmacies are to follow Professional Practice Policy – 68: Cold Chain Management of Biologicals.

*Check ImmsBC and CareConnect for complete patient history of immunizations.

Pfizer Vaccine Product (COVID-19 mRNA Vaccine)

For COVID-19 vaccine product details, refer to BC Immunization Manual Part-4 Biological Products Pfizer-BioTech (COVID-19 mRNA Vaccine BNT162b2), which includes information on doses and schedule, administration procedures, storage and handling, dilution requirements, contra-indications, precautions, special considerations, and adverse events.

Pfizer vaccine multi-dose vial contains 0.45 mL white to off-white suspension and does not contain a preservative. Vaccine may be stored at refrigerated temperature (+2°C to +8°C) for 31 days.  Vaccine must be diluted prior to administration with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP. After dilution, the vial contains 6 doses of 0.3 mL, with 30 micrograms mRNA each.  Diluted vaccine must be kept between +2°C to +25°C and used within 6 hours from the time of dilution. For details, see Vaccine storage and handling, and Dose preparation and extraction.

For medical questions, contact Pfizer Medical Information 1-800-463-6001 or visit pfizermedicalinformation.ca. Inquiries can also be sent by email: CanadaCSVaccine@Pfizer.com

Doses and schedule:

  • Individuals 12 years of age and older: 2 doses given as 0.3 mL IM, 21 days apart
    • This is the schedule authorized by Health Canada.  As of August 9, 2021, first dose recipients can be offered to book dose 2 at 4 weeks (28 days) after dose 1. The preferred interval between dose 1 and 2 is 6 to 8 weeks, with the exception of those living and working in outbreak communities, at the direction of the Medical Health Officer, and individuals who meet criteria for an expedited dose 2.
    • The minimum interval between doses is 18 days. For optimal responses, immunizers should observe the recommended intervals; however, doses given earlier than recommended may still be considered valid and need not be repeated if minimum intervals are observed.
    • The vaccine series should be completed with the same COVID-19 vaccine product. If it is not possible to determine which product was used for the first dose, or if the same product is unavailable, the second dose may be given with an available mRNA product.
    • NACI recommends that mRNA vaccine (Pfizer-BioNTech or Moderna) can be offered as a second dose to individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine, unless contraindicated. A new patient resource (.pdf) "Why your 2nd dose is so important" contains information about mixing vaccine brands.

Third doses for individuals who are immunocompromised

Updated September 14, 2021: Following the provincial announcement that third doses are recommended for some people who are immunocompromised, BCCDC has updated Part 4 – Biological Product page for Pfizer Vaccine.

For individuals 12 years and older who are severely immunocompromised, a 3-dose primary series is recommended. Moderna COVID-19 vaccine is preferentially recommended for the 3rd dose, which should be provided at least 28 days after the 2nd dose. If Moderna is unavailable, Pfizer vaccine can be given.

Severely immunosuppressed includes individuals who:

  • Have had a solid organ transplant (heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant).
  • Since January 2021, have been treated for and/or are receiving active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematological disorders (e.g., leukemia, lymphoma, or myeloma).
  • Since January 2020, have received treatment with any anti-CD20 agents (i.e., rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab or tositumomab).
  • Since January 2020, have been treated on B-cell depleting agents (i.e., epratuzumab, MEDI-551, belimumab, BR3-Fc, AMG-623, atacicept, anti-BR3, alemtuzumab).
  • Have combined immune deficiencies affecting T-cells, immune dysregulation or type 1 interferon defects.
  • Since September 2019, have had bone marrow or stem cell transplant or are still taking immunosuppressant medications related to transplant.

Information on how to obtain third doses for people who are immunocompromised has been added to BCCDC’s Vaccine Considerations and Registration and Eligibility pages.

Vaccine Storage and Handling

  • Pfizer vaccine storage: 
    • Ultra-low temperatures (-90°C to -60°C) up to end of its expiry.
    • Freezer temperatures (-25°C to -15°C) for up to 2 weeks.
    • Refrigerated temperature (+2°C to +8°C) for 31 days
    • Room temperature (up to +25°C) for up to 2 hours prior to dilution; for up to 6 hours from time of dilution (total 8 hours at room temperature).
  • Prior to dilution:
    • Frozen vials must be thawed before mixing:
      • 2-3 hours at refrigerated temperature (+2°C to +8°C).
      • 30 minutes at room temperature (up to +25°C).
    • Vaccine may be stored at refrigerated temperature (+2°C to +8°C) for 31 days.
    • Vaccine may be at room temperature (up to +25°C) for up to 2 hours prior to dilution.
    • Never refreeze thawed vials.
  • After dilution:
    • Vaccine must be diluted with 0.9% Sodium Chloride Injection, USP. See Dose preparation and extraction.
    • Diluted vaccine must be kept between +2°C to +25°C and used within 6 hours from the time of dilution. Discard any unused vaccine after 6 hours.
    • After dilution, the vaccine vials can be handled in room light conditions. Avoid exposure to direct sunlight and ultraviolet light.
    • Diluted vaccine can be pre-loaded into syringe for up to 6 hours. Clearly label pre-filled syringe date/time of dilution.
    For more information on storage and handling and temperature monitoring refer to COVID-19 Pfizer Vaccine shipping, storage, thawing and use guidelines, BCCDC Appendix E: Management of Biologicals and Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine.

Dose preparation and extraction

  • Pfizer vaccine multi-dose vials must be diluted prior to administration.  The multi-dose product contains no preservative.
    • The contents of the vial must be diluted with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP. Do not add more than 1.8 mL of diluent.
      • 1 vial of NaCl diluent to be used for 1 Pfizer vaccine vial.
      • Only use 0.9% Sodium Chloride Injection, USP as the diluent.
      • Discard any remaining diluent.
    • Gently invert vaccine vial 10 times before mixing. Do not shake.
    • A 21-gauge needle or narrower is recommended to dilute the vaccine, to prevent a larger opening in the vial stopper that may allow vaccine to leak.
    • After diluting the diluent into the vaccine vial, withdraw 1.8 mL of air from the vaccine vial into the empty diluent syringe prior to removing the needle from the vial. This will prevent loss of vaccine from the vial through forceful expulsion under pressure.
  • After dilution, the vial contains 6 doses of 0.3 mL.
    • Gently invert the diluted vial 10 times to mix. Do not shake.
    • Diluted vaccine will be an off-white suspension. Inspect vials to confirm there are no particulates and no discoloration.
    • Record date and time of dilution on vaccine label.
    • Store diluted vaccine at refrigerated temperature or at room temperature (i.e., +2°C to +25°C), away from direct sunlight.
    • Use within 6 hours.
  • Extracting doses:
    • Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. Standard syringe and needles may not facilitate the extraction of a 6th dose from a single vial.
    • For strategies on extracting maximum number of doses see Part 4 Biological Product for Pfizer (administration section).
  • For details on preparing product, review Pfizer CDC vaccine.ca.

Recapping of the needle

  • Recapping of the needle following preparation of the vaccine may be required for various reasons such as transport and storage.
  • When choosing to recap the needle following preparation of the vaccine, follow the Passive Needle Recapping Technique.
  • Recapping should NOT be done following vaccine administration.
  • As biological product administration requires a safety-engineered needle, it is important to engage safety mechanism on the needle immediately following administration of the biological product. Immediately discard needle and attached syringe in hard sided, labeled sharps container.
  • Any needle stick injuries should be reported as per Health Authority/Employer protocol.

Vaccine Expiry

Updated Aug. 27, 2021: Health Canada authorized an update to the Pfizer-BioNTech COVID-19 Vaccine Product Monograph to allow a 3-month extension to the expiry date for all Pfizer vaccine vials with expiry dates of August 2021 through February 2022 printed on the vial and carton labels, provided that ultra-low temperature storage has been maintained (i.e., -90°C to -60°C). See updated list of expiry dates here.

Expiry date interpretation

As per BCCDC, the expiry date on vaccines should be interpreted as follows:

  • When specified as month/year, product expires on the last day of the month and may continue to be administered until the end of the month (e.g., expiry of January 2021 means January 31, 2021, and may be used until 11:59 pm in the local time zone).
  • When specified as a day/month/year, product expires at the end of the day of expiry i.e., may be administered up until the last minute of the labelled expiry day, within the time zone of use (e.g., product expiring on April 2, 2021, may be used until 11:59 pm on April 2, in the time zone).

What to do with expired product

  • Remove expired vaccines from the refrigerator and clearly label/mark not to be used.
  • Do a thorough inventory of the numbers of expired doses (including partial vials).
  • Record inventory wasted in the ImmsBC system.
  • Dispose of the vaccines using your regular biomedical waste disposal procedures for vaccines.

Ordering and Distribution of Vaccine and Supplies

BCCDC central depot will ship vaccine at frozen state (-25°C to -15°C) to Distributors/Wholesalers. Vaccine is stored at thawed state (+2°C to +8°C) at Distributors. A pre-determined allocation of Pfizer doses is shipped directly to pharmacy sites from the Distributor at refrigerated temperature (+2°C to +8°C).  

  • Vaccine can be transported at +2°C to +8°C for a cumulative 12 hours.
  • Any hours used for transport at +2°C to +8°C count against the 31-day limit for storage at +2°C to +8°C.
  • Check documentation/temperature transport tracking tool upon receipt. 
  • Record date/time product thawed and date/time vaccine spent in transit. 
  • Vaccines will arrive in a box of 25 vials with 6 doses per vial containing a total of 150 doses (this may change near the tail end of the pilot and will likely be different during the booster campaign that is anticipated for later this year or early next year).

Supplies

Diluent (0.9% Sodium Chloride Injection USP) and ancillary supplies e.g., safety needles and syringes, will be provided along with the vaccines (supply quantities will match the number of vaccine doses), and are available at no cost through the Provincial Health Services Authority (PHSA) supply chain.

Supplies Size Quantity per 150 doses
Maverin (Antmed) 1ml LDS syringe 200/box 1 box
Sol- Care 25G x 1” LDS needles  100/box 2 boxes
Accel Disinfectant Wipe, 6x7 60 wipes/container 1 container
Sharp Container 7.6L 1 container 1 container
Alcohol Prep Swab, Loris 70%  200/box 1 box
Bandage Adhesive Round  200/box 1 box

*Note that McKesson will distribute needles and syringes only.

 

Ordering Instructions

  • Orders should only be made when you have used or booked appointments to use up your vaccines within 1.5 weeks.
  • Orders for additional doses are in multiples of 150 doses and will be approved based on throughput, appointments booked and inventory on hand.
  • Order deadline is Sunday 11:59pm PST each week.  
    • Orders received Monday to Sunday of each week are sent to distributors by the following Thursday (e.g., submission between August 23-29, you would expect to receive the vaccine between September 3 and 6).
    • Distributors will then send the vaccines to you by Friday and no later than Tuesday after receive the vaccines.
  • You do not need to submit an order form at the beginning of the pilot, we will supply you with 150 doses to start the campaign. Pharmacies starting August 24, will receive their doses between August 20 and 24.  Your first appointments can start on August 25 as your pharmacy will not be active to citizens until August 24.
  • Click here to submit your order form.
     

Vaccine Eligibility Screening and Verification

  • Pfizer vaccine is indicated in individuals 12 years of age and older.
  • The minimum age for vaccine receipt is based on year of birth (i.e., the vaccine may be offered to individuals who will be turning 12 years of age within the current calendar year), per Provincial Health Officer recommendations.
  • Appointments that are booked through the ImmsBC system by patients directly would have been screened by the system or provincial call centre prior to the appointment being made.
  • Pharmacies must review patient identification (ID) and ensure ID matches the patient profile on ImmsBC or alternatively PharmaNet.
  • The ImmsBC system has a built in Check Eligibility functionality built-in that confirms the patient's eligibility to receive the vaccine and is integrated with PIR and EMPI.
  • Check ImmsBC/CareConnect/PharmaNet to confirm history of a COVID-19 vaccine and any related Adverse Events Following Immunizations (AEFIs).  Both ImmsBC and CareConnect are integrated with the PIR.
    • Verbal confirmations should only be used as a secondary source of verification, as patient interviews are not 100% reliable.
  • Review BCCDC’s COVID-19 Vaccine Screening Checklist.
    • See Contraindications and Precautions in BCCDC’s Healthcare Provider Q&A.
    • COVID-19 mRNA vaccine should not be given to an individual if they have a:
      • History of anaphylactic reaction to a previous dose of an mRNA COVID-19 vaccine or to any component of the vaccine. These individuals should be offered an adenovirus vector COVID-19 vaccine and observed for a least 30 minutes after immunization.
    • Myocarditis/ Pericarditis: The 2nd dose of COVID-19 mRNA vaccine should be deferred in those who experienced a physician-diagnosed myocarditis or pericarditis event following the first dose with no other cause identified, until further information about the risk of recurrence is available. Deferral is not required for those with a prior history of myocarditis or pericarditis that is unrelated to COVID-19 mRNA vaccines and are no longer being followed by a medical professional for heart issues.
      • Updated September 8, 2021: Pericarditis/ Myocarditis with COVID-19 mRNA Vaccines in Adolescents 12 -17 - Excerpt from NACI summary statement:
        • There have been reports of myocarditis and/or pericarditis after immunization with mRNA COVID-19 vaccines in Canada and internationally. Based on international reports as of August 19, 2021, cases of myocarditis and/or pericarditis occur more often in adolescents and adults under 30 years of age, more often in males than in females, and more often after a second dose of an mRNA vaccine than after a first dose.
        • While follow-up is ongoing, available data indicate that the majority of individuals affected have responded well to conservative therapy, and tend to recover quickly.
        • Recently, a higher rate of cases of myocarditis and/or pericarditis has been reported after the administration of the Moderna vaccine compared to the Pfizer-BioNTech vaccine, although verification of this potential difference is ongoing.
      • Both the Pfizer-BioNTech and Moderna vaccines continue to be recommended in B.C. for this age group.
    • The 2nd dose of COVID-19 mRNA vaccine should be deferred in those who experienced a physician-diagnosed myocarditis or pericarditis event following the first dose with no other cause identified, until further information about the risk of recurrence is available. Deferral is not required for those with a prior history of myocarditis or pericarditis that is unrelated to COVID-19 mRNA vaccines and are no longer being followed by a medical professional for heart issues. 
  • Non-residents of B.C/ Non-Canadians are able to be vaccinated at a community pharmacy:
    • Anyone living, working or studying in B.C. during the pandemic can receive the COVID-19 vaccine, even if they are not a Canadian citizen or permanent resident (with ID showing they meet the age/current eligibility requirement).
    • Pharmacies will be reimbursed for this service. As with any other patient, a PHN is to be generated for the patient if they do not currently have one. No one that is eligible (as per current criteria) is to be turned away for an appointment they have booked. Name and date of birth of patient is required.
  • BCCDC has created a Healthcare Provider Q&A which includes general and evolving information about COVID-19 vaccines currently used in B.C. It can be found on the COVID-19 vaccination toolkit for health professionals webpage.

COVID-19 vaccinations outside B.C. and Canada

  • For COVID-19 vaccines received in another province, patients can submit proof of an official vaccination record which will be entered into the Provincial Immunization Registry. For more information, see Vaccine Registration and Eligibility.
  • To support health care providers with approaches for individuals who have received COVID-19 vaccination outside of Canada review World Health Organization (WHO) Emergency Use Authorization (EUA) Qualified COVID-19 Vaccines.
    • Individuals who have received a complete series with a vaccine that is WHO EUA qualified are considered fully vaccinated and no further doses are required. However, one additional dose of a COVID-19 mRNA vaccine may be provided for individuals upon request if they have been vaccinated with a WHO-approved vaccine series that is not authorized in Canada. The minimum interval between the preceding dose and the additional dose is 4 weeks.
    • Individuals who have received a series with a vaccine that is not WHO EUA qualified should be offered a full COVID-19 vaccine series using a vaccine available in BC. There is no minimum interval required when restarting the series following receipt of a non-WHO approved vaccine.
    • Individuals who have received a first dose of a COVID-19 vaccine overseas that is also available in BC should receive the same vaccine for their second dose if readily available, and if they meet the current BC eligibility criteria for 2nd dose (i.e., at least 4 weeks following first dose). If the vaccine they received for their first dose is not available in BC, but the same type of vaccine is available, this should be offered. A 6 to 8 week interval between doses is recommended. A minimum interval of 4 weeks is acceptable, if required.

Informed Consent

Post-immunization Monitoring and Aftercare

  • Patients are to remain in a designated area for 15-minute observation period following COVID-19 vaccine receipt. If there is a specific concern about a possible allergy to a component of the COVID-19 vaccine being administered, an extended period of observation post-vaccination of 30 minutes may be warranted. 
  • Provide the patient a record of immunization, as per PharmaCare policy manual section 8.10. At a minimum the record should include the patient name, dose number, date of administration, product given, lot number and pharmacy information. See example vaccine record card.
  • Encourage patients to sign up to Health GateWay to access their digital immunization record. ImmsBC data is fed into the Provincial Immunization Registry which is subsequently uploaded to Health Gateway where patients can access the health records themselves.
  • Provide patients the COVID-19 Vaccine After care sheet, which includes information on possible side effects and what to expect over the next few days after the vaccine.
  • If there is any intervention or adverse effects, you will need to document this in the ImmsBC system.

PharmaNet Data Entry

ImmsBC Report for PharmaNet Data Entry

In addition to needing to the complete the vaccine administration process in ImmsBC, PharmaNet claim entry will also be required.

A custom report has been developed in ImmsBC for pharmacies to print out your daily summary of vaccinations with all the fields of data you need for data entry into PharmaNet.  Please refer the ImmsBC instructions in accessing this report..

PharmaNet claim entry:

  1. Use the product identification number (PIN) as assigned by PharmaCare. See Vaccine PIN.
  2. The administering pharmacist should be the prescriber.
  3. Follow the protocol for entry of the “Directions for Use” (Sig) field (see below).
  4. Quantity is the amount administered to the patient, in millilitres (i.e., 0.3 mL for Pfizer vaccine).
  5. Days supply for first dose is 18 days*. Days supply for second dose is 1 day.

Note that the Health Canada product monograph authorizes 21 days between doses. In B.C., patients can be offered dose 2 at 28 days, although the preferred interval between doses is 6-8 weeks. The minimum interval between doses is 18 days. 

“Directions for Use” field

The following table outlines the data entry in the “Directions for Use” or “Sig” field:

Data element

Order in text

Allowable value

Description

LOT

1st

Lot number

Lot number as provided on the vial

LOT

2nd

Left

Arm/site where the vaccine was injected

Right

The information is recorded in the “Directions for Use field” in the above order separated by and underscore “_” i.e., “LOT_SITE”

Example:

Lot

Site

Directions for Use

XYZ123-12

Left

XYZ123-12_LEFT

XYZ123-12

Right

XYZ123-12_RIGHT

*Note: If there is a hyphen in the Lot number, include it when entering the number.

Vaccine PIN

Pfizer vaccine PIN is 66127303

Claim Adjudication Results

COVID-19 immunizations will be reimbursed via the usual process for vaccinations.  

At the time of submission, PharmaNet will indicate that the immunization is NOT a benefit. This is expected; reimbursement is done by a secondary process, which identifies the number of immunizations administered by a pharmacy, irrespective of adjudication results. You do not need to reverse and resubmit the claim.

Inventory Management

The following inventory must be recorded in the provincial ImmsBC system:

  1. Inventory received
  2. Inventory wasted

Follow the ImmsBC instructions to accept inventory and document wastage. 

Returning product

Vaccine returns is not permitted from pharmacies, unless in exceptional circumstances, due to the inability to guarantee cold chain management.

Transferring products between pharmacies

Transfer of Pfizer Vaccine to other pharmacies is not permitted in this pilot.

Reimbursement

  • Effective March 31, 2021, a $5.90 supplement will be temporarily added to PharmaCare’s vaccination administration fee for COVID-19 vaccines in pharmacies.
  • PharmaCare’s fee for publicly funded vaccines is $12.10. The supplement applies to COVID-19 immunizations only. With the supplement added to the vaccine administration fee, pharmacies will receive $18.00 for every COVID-19 vaccine they administer

Reporting Cold Chain Incidents

If a temperature excursion occurs while vaccine is in your pharmacy:

  1. Quarantine affected vaccine and label as “Do Not Use”.
  2. Receiving site notifies IBCOC_Operations@phsa.ca as soon as possible. Call 1-250-686-6061, if after hours.
  3. Cold chain consultation process initiated.
    • Report incident to local public health for determination of vaccine* (Pharmacies in FHA only). If after hours/unable to contact local public health and your need for information is urgent, contact the Provincial Health Duty Officer at 1 (250) 686-6061.
    • Cold chain incident form completed. For instructions and form, see the Vaccine Management webpage.

Picture2_0.png

4. Within 24 hours, the incident must be resolved, and a report submitted to IBCOC_Operations@phsa.ca with the following information:

  • Date of incident
  • Location of incident
  • Situation surrounding incident:
    • Excursion temperature(s) and duration
    • Lot number, expiry
    • Detailed description of event
    • Number of affected doses
    • Impact on clinic (e.g., closed early, cancelled, clients redirected to alternate side)
  • Recommendations

5. Upon receipt of this report, the Immunize BC Operations Centre will be responsible to report the incident to the National Operations Centre (NOC).

  • Record inventory wasted in the ImmsBC system.

See BCCDC SOP for COVID-19 Vaccine Cold Chain Incident Reporting Process

*For Pharmacies in Fraser Health Authority Only:

Reporting Adverse Events Following Immunizations (AEFI)

  • According to BCCDC, an adverse event following immunization (AEFI) is defined as an untoward event temporarily associated with immunization that may or may not have been caused by the vaccine or immunization process.
  • The AEFI with COVID-19 Vaccine Case Report Form is an abbreviated version of the standard AEFI case report form and is available in the COVID-19 Vaccination Toolkit for Health Professionals. It is intended for use by community vaccine providers (i.e., non-public health professionals) and the reporting of AEFIs associated with COVID-19 vaccination. See Adverse Events Following Immunization (AEFIs) for details.
  • For criteria on reporting AEFIs, and to help healthcare providers interpret AEFIs and their implications for subsequent immunization, see BC Immunization Manual Part 5 – Vaccine Associated Adverse Events.
  • Pharmacist are encouraged to record relevant Adverse Drug Reactions (ADEs) in PharmaNet in addition to the AEFI form.
  • You will also need to enter any AEFIs or intervention into the ImmsBC system.

Reporting of sub-dose vials

Inventory reconciliation is required in ImmsBC to record any variance in doses.  Please follow the instructions on the ImmsBC system to ensure that the inventory for your pharmacy is accurate and make the necessary adjustments as needed including for sub-numbered doses.  

In addition, see COVID-19 Sub-Numbered Dose Vial Reporting procedures if a Pfizer vial yields less than labelled doses (6). A survey must be completed and reported to IBCOC (IBCOC_Operations@phsa.ca) if an excessive rate of sub-dose vials is observed. A rate would be considered excessive if >5% of vials yield less than labelled number of doses.

Note: A common error in completing the form relates to the columns E and F (# of vials used on day of report and # of vials from which expected number of doses are retrieved). The # of vials used on the day of the report is needed to establish a correct denominator and the # of vials which yielded the expected amount allows us to calculate a numerator. If your teams can do their best to provide the numbers it would be much appreciated.

Reporting receipt of damaged vials or missing vials

Inventory reconciliation is required in ImmsBC to record any variance in doses.  Please follow the instructions on the ImmsBC system to ensure that the inventory for your pharmacy is accurate and make the necessary adjustments as needed including receipt of damaged or missing vials.  This should take place at the same time you are receiving the doses into your "Supply Location" (virtual fridge) on ImmsBC.

B.C. is required to report to the National Operations Centre (NOC) on the acceptability of all vaccines and other materials received in-province via a federal contract with the supplier.

See Post-Arrival Documentation & Administration Protocols if you have received damaged or missing vials for how to report. Reports should be sent to IBCOC (IBCOC_Operations@phsa.ca).

Registering for CareConnect

  • Each pharmacy will need to have completed the CareConnect Privacy and Security agreement in order to gain access to the ImmsBC system.
  • If you already have access to CareConnect that means you already completed the agreement. 
  • Getting CareConnect access:
  • Complete the following survey form through this link -   Enrol in CareConnect.  Once completed, the CareConnect team send the instructions for the next steps.
    • IMPORTANT NOTE: You may have received information on CareConnect enrolment through the College of Pharmacists of BC email in mid-March.  The above link is the same link shared by the College. 

Resources

Watch Training Sessions

The BCPhA held two webinar training sessions on the Pfizer pilot program in community pharmacy in August. Learn more and watch the recordings below: